Baltic pharma market 1999

1
Baltic pharma market 1999 2004

• Developments, changes and possible future trends

2
Agenda

• Baltic pharma market
• Innovative and Generic segments
• New launches
• Reimbursed and Non-reimbursed segments

3
Baltic pharma market sales 1999 2004, retail
prices, Euro
All sums in Euro
2004 Pharma market, Euro ACG 99-03
World 432 billion 10
Europe 128 billion 9
BALT ACG 13.0
IMS Dataview data, 2004
IMS HEALTH MIDAS, MAT Dec 2004
4
Baltic pharma market structure by country in
1999 2004, retail prices,
2004

EST 21.8
LV 24.0
LT 54.2
IMS Dataview data, 2004
5
Baltic pharma market sales by country 1999
2004, retail prices, Euro
All sums in Euro
EST ACG 19.6
LV ACG 6.1
LT ACG 14.6
IMS Dataview data, 2004
6
Baltic pharma market sales per capita by country
1999 2004, retail prices, Euro
All sums in Euro
EST ACG 19.6
LT ACG 14.6
LV ACG 6.1
IMS Dataview data, 2004
7
Agenda

• Baltic pharma market
• Innovative and Generic segments
• New launches
• Reimbursed and Non-reimbursed segments

8
Baltic pharma market structure in 1999 2004,
retail prices,
1999

2004
Inno 48.6
Inno 40.8
Gen 59.2
Gen 51.4
IMS Dataview data, 2004
9
Estonian pharma market structure in 1999
2004, retail prices, Euro
1999
2004
50.7
56.8
43.2
49.3
IMS Dataview data, 2004
10
Baltic pharma market sales in 1999 2004,
retail prices, Euro
BALT ACG 13.0
All sums in Euro
ACG Inno 17.1
ACG Gen 9.9
IMS Dataview data, 2004
11
Estonian pharma market sales in 1999 2004,
retail prices, Euro
Estonia ACG 19.6
ACG
Inno 22.4
Gen 16.6
IMS Dataview data, 2004
12
Baltic pharma market structure in 1999 2004,
units
1999

2004
Inov 14.7
Inno 19.8
Gen 80.2
Gen 85.3
IMS Dataview data, 2004
13
Estonian pharma market structure in 1999
2004, units
2004
1999
25.0
31.6
75.0
68.4
IMS Dataview data, 2004
14
Agenda

• Baltic pharma market
• Innovative and Generic segments
• New launches
• Reimbursed and Non-reimbursed segments

15
Baltic pharma market structure in 1999 2004,
retail prices,
BALT 100

New Inno 27.4
New Gen 24.6
Old 48.0
IMS Dataview data, 2004
16
Estonian pharma market structure in 1999 2004,
retail prices,
ACG
New Inno 22.1
New Gen 21.9
Estonia
Old 56.0
IMS Dataview data, 2004
17
Baltic pharma market sales in 1999 2004, units
2004
units
New Inno 8.2
New Gen 35.5
Old 56.2
IMS Dataview data, 2004
18
Estonian pharma market structure in 1999 2004,
units
2004
New Inno 8.2
New Gen 30.8
Estonia
Old 61.0
IMS Dataview data, 2004
19
Generics share in pharma markets
Growth Constant
Generics
Brands
11
6
7
8
7
1
24
5
31
6
21
7
-3
2
16
8
18
5
Source IMS HEALTH MIDAS, MAT Dec 2004
20
Agenda

• Baltic pharma market
• Innovative and Generic segments
• New launches
• Reimbursed and Non-reimbursed segments

21
Baltic pharma market RX sales in 2000 2004,
retail prices, Euro
All sums in Euro
IMS Dataview data, 2004 National Sick Funds data,
2004
22
Baltic pharma market RX sales structure in 2000
2004, retail prices, Euro
2004

Non-re 27.6
Co-pay 30.3
Reimb 42.1
IMS Dataview data, 2004 National Sick Funds data,
2004
23
Estonian pharma market RX sales structure in
2000 2004,
2004
2000
Non-re 13.2
Co-pay 36.1
Estonia
Reimb 50.7
IMS Dataview data, 2004 National Sick Funds data,
2004
24
Baltic pharma market RX reimbursed sales per
capita by country in 2004, retail prices, Euro
Euro
IMS Dataview data, 2004 National Sick Funds data,
2004
25
Baltic pharma market RX reimbursed sales per
capita by country in 2004, retail prices, Euro
Co-payment

Reimbursed
41.9
58.1
41.6
58.4
45.1
54.9
41.1
58.9
IMS Dataview data, 2004 National Sick Funds data,
2004
26
Baltic pharma market RX expenditures per capita
by country in 2004, retail prices, Euro
Euro
IMS Dataview data, 2004 National Sick Funds data,
2004
27
Baltic pharma market RX expenditures structure
per capita by country in 2004, retail prices,
Euro
Patient
State
All sums in Euro
51.8
48.2
46.4
53.6
58.4
41.6
51.3
48.7
IMS Dataview data, 2004 National Sick Funds data,
2004
28
European Union expenses on pharmaceuticals in
2001, USD per capita
2001, OECD Health Data 2001, IMS Data 2001,
National Sick Fund data

29
European Union expenses on pharmaceuticals in
2001, USD per capita
2001, OECD Health Data 2001, IMS Data 2001,
National Sick Fund data

30
European Union Healthy Life Expectancy (HALE) at
birth,years
2001, WHO Data

31
European Union Healthy Life Expectancy (HALE) at
birth,years
2001, WHO data

32
Baltic pharma market state pharma spending per
capita by country planed in 2005, retail prices,
Euro
Versus 2004
Euro
Reimb 10.7 Centr 6.7
Reimb 3.0 Centr 38.0
Reimb 17.0 Centr -16.5
Reimb 12.82 Centr 60.88
IMS Dataview data, 2005 National Sick Funds data,
2005
33
Conclusions
The Baltic pharma market is very small comparing
with other European and Global pharma markets but
demonstrates relatively high growth rate.
Generics have substantially higher shares in
the Baltic pharma market comparing with the
markets of Western Europe and the USA. The total
generic segment of the Baltic market has shrank a
little during the last years but newly launched
generics continued to capture the major share of
the new products segment in volume and a half of
it in value. The State pharma financing in the
Baltic States is among the lowest in the European
Union. It is increasing every year but still
remains far below the European average. One of
the Health Care efficiency measures in the Baltic
Sates - Healthy Life Expectancy at birth (HALE) -
is among the lowest in the European Union. A good
status of population health is an outcome of many
factors, including allocation of sufficient
financial recourses for an effective innovative
pharmacological treatment.
34
(No Transcript)